By Adria Calatayud

 

Oncimmune Holdings PLC said Thursday that it has signed a new contract with Swiss pharmaceutical giant Roche Holding AG to profile autoantibodies in patient samples collected during cancer immunotherapy trials.

The U.K. immunodiagnostics group said the contract, for the use of Oncimmune's SeroTag biomarker discovery platform to explore autoantibody profiles in patients that received cancer immunotherapy, will start immediately. Initial results are scheduled to be provided to Roche within three months, with project completion by November, Oncimmune said.

Oncimmune Chief Executive Adam M Hill said this is the largest contract the company has signed to date and builds upon the collaborative work between the two companies in recent months.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

May 28, 2020 03:04 ET (07:04 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Oncimmune (LSE:ONC)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Oncimmune Charts.
Oncimmune (LSE:ONC)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Oncimmune Charts.